Advanced Filters
noise

Arlington, Virginia Clinical Trials

A listing of Arlington, Virginia clinical trials actively recruiting patient volunteers.

Found 1,276 clinical trials
C Carrie Friedman

Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.

This is a Phase 1b/2, single-arm, open-label, dose-escalation study including 2 stages: Phase 1b: Dose-Escalation Stage (Single-Dose and Consecutive-Dose Periods) Phase 2: recommended Phase 2 dose (RP2D) of chiauranib will be given to all patients enrolled in this phase once daily for 28-day cycles continuously with no interruption between cycles.

18 years of age All Phase 1/2

A Study to Learn About The COVID-19 (Study) Vaccine (Called COMIRNATY) in People That Are Less Than 21 Years Old.

The purpose of this clinical trial is to learn about the safety and effects of the study vaccine (called COMIRNATY) for the potential prevention of COVID-19. This study is seeking participants who: Are age <21 years. Have presentation to participating medical center with evaluation in Emergency Room and/or hospitalization. Received …

- 20 years of age All Phase 4
F For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)

[18F]PF-06445974 to Image PDE4B in Major Depressive Disorder Using PET

Background Major depressive disorder (MDD) is a psychiatric condition. People with MDD have occasional bouts of depressive symptoms; these bouts are called major depressive episodes (MDEs). Researchers want to know if people having MDEs have lower levels of an enzyme called PDE4B in their brains. Primary Objective: To determine whether …

18 - 70 years of age All Phase 1
J Jennifer Mont

NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors

The goal of this clinical trial is to learn about the safety of NEROFE and doxorubicin and how well it works in patients with advanced/unresectable or metastatic solid KRAS-mutated and ST-positive solid tumors. The main question it aims to answer is to find the recommended dose and scheduled for the …

18 years of age All Phase 1
I Inger Ljungberg, MPH

Intravesical Lactobacillus for Urinary Symptoms Among People With NLUTD Who Use Indwelling Catheters

The objectives of the proposed research among this population are: 1) to define clinically meaningful change (i.e. differentiating states of health and illness) with respect to urinary symptoms, urine inflammation, cultivable bacteria, and the urine ecosystem; and 2) to determine the optimal intravesical Lactobacillus RhamnosusGG (LGG®) dose to be used …

18 years of age All Phase 2

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.

18 years of age All Phase 1
J John Ragheb, MD

A Feasibility Safety Study of Benign Centrally-Located Intracranial Tumors in Pediatric and Young Adult Subjects

The goal of this prospective, non-randomized, single-arm, feasibility study is to develop data to evaluate the safety and feasibility of ExAblate 4000 treatment of benign intracranial tumors which require clinical intervention in pediatric and young adult subjects. Indication of Use: Ablation of benign intracranial tumors in children and young adults …

5 - 22 years of age All Phase N/A
J Joaquina Baranda, MD

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

Background Metastasis is the spread of cancer from one organ to a nonadjacent organ. It causes 90% of cancer deaths. No treatment specifically prevents or reduces metastasis. Researchers hope a new drug can help. It stops cancer cells from growing and spreading further and possibly shrink cancer lesions in distant …

12 - 120 years of age All Phase 1
M Meera Chitlur, MD

SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors

Phase IV multi-center, US-centric, open-label, safety study enrolling participants with Hemophilia A or B with inhibitors12 years of age and older, who are either on long term prophylactic treatment (e.g., emicizumab) at risk of experiencing a breakthrough bleeding event (BE), or who are not on prophylactic treatment who may need …

12 - 100 years of age All Phase 4
A Alexandra Crawford, MPH

Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer

The purpose of this research study is to compare the effects (good and bad) on women and their cancer using proton radiation therapy. This study is being done to see if proton radiation therapy will prove to be beneficial for women with early stage breast cancer. A clinical study is …

50 years of age Female Phase 2

Simplify language using AI